Allyx Therapeutics

Allyx Therapeutics was founded in 2019 by a group of seasoned biopharmaceutical industry executives, venture capitalists, and scientific experts. The company aims to provide a novel approach to protecting synapses for patients with neurodegenerative diseases. Its lead compound, ALX-001, is a first-in-class oral therapy with a unique mechanism of action on mGluR5 and is currently in clinical development for Alzheimer's disease.